Company / R&D per Share
Apellis Pharmaceuticals, Inc. R&D per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$2.38
FY2025
5-year range
$2.38 / $4.54
FY2021-FY2025
Trend
-13.3%
vs FY2024
Sector context
#92 of 208
Health Care
What the data says
At $2.38, Apellis Pharmaceuticals, Inc.'s r&d per share ranks #92 of 208 in the Health Care sector. R&D per Share has declined for 5 consecutive years, from $4.69 in FY2020 to $2.38 in FY2025.
Based on SEC 10-K filings.
2.38 in FY2025 with a 5-year CAGR of -12.7%.
Declined from $3.20 to $2.38 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- -15.7%
- 5-Year CAGR
- -12.7%
- 10-Year CAGR
- -
Sector benchmark
#92 of 208 in Health CareTop 44% of 208This company $2.38 Sector average $28.82
▼
-91.8% below sector average
Key checks
Key Insights
- Apellis Pharmaceuticals, Inc.'s r&d per share has declined for 5 consecutive years.
- In FY2025, r&d per share decreased 13.3% year-over-year.
- Ranks #92 out of 208 companies in the Health Care sector.
- Peak r&d per share was recorded in FY2020.
Company context
Key Data Points
- Altman Z-Score -0.60 (distress zone, below 1.8 threshold)
- Negative profit margin: -25.3%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.38 | -13.3% |
| FY2024 | $2.74 | -14.4% |
| FY2023 | $3.20 | -19.4% |
| FY2022 | $3.97 | -12.6% |
| FY2021 | $4.54 | -3.1% |
| FY2020 | $4.69 | +32.1% |
| FY2019 | $3.55 | +83.5% |
| FY2018 | $1.94 | -33.4% |
| FY2017 | $2.91 | +6.6% |
| FY2016 | $2.73 | +15.1% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026